Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design

Journal of Virology

Volumn 75, Issue 19, 2001, Pages 9210-9228

  Novitsky, V ^a   Rybak, N ^a   McLane, M F ^a   Gilbert, P ^a   Chigwedere, P ^a   Klein, I ^a   Gaolekwe, S ^a   Chang, S Y ^a   Peter, T ^a   Thior, I ^a   Ndung'U, T ^a   Vannberg, F ^a   Foley, B T ^a   Marlink, R ^a   Lee, T H ^a   Essex, M ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAG PROTEIN; HLA ANTIGEN CLASS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN;

ADOLESCENT; ADULT; ALLELE; ARTICLE; BOTSWANA; CHROMIUM 51 RELEASE; CONSENSUS SEQUENCE; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FEMALE; GEOGRAPHIC DISTRIBUTION; HLA MATCHING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1C; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POPULATION GENETICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RELIABILITY; STAINING; VACCINATION; VIRUS TYPING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; AMINO ACID SEQUENCE; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; GENES, GAG; GENES, NEF; GENES, REV; GENES, TAT; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; T-LYMPHOCYTE SUBSETS;

EID: 0034847979     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.19.9210-9228.2001     Document Type: Article

References (117)

1. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS
2. The HIV-1 regulatory, proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals
3. Analysis of cytotoxic T-lymphocyte (CTL) responses against the regulatory HIV-1 proteins Rev and Tat in HIV-1-infected individuals and identification of novel CTL epitopes
4. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
5. + T helper cells in the cytotoxic T lymphocyte response to HIV-1
6. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
7. Identification of novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte epitopes predicted by the HLA-A2 supertype peptide-binding motif
8. Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: Rapid characterization of CTL responses by enzyme-linked immunospot assay
9. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
10. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen
11. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians
12. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C Isolates of Ethiopian AIDS patients
13. - cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
14. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
15. T lymphocyte responses in HIV-1 infection: Implications for vaccine development
16. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine
17. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine
18. Cytotoxic Tlymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development
19. Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: Relevance to HIV-1 vaccine trials in Uganda
20. Characterization of subtype A HIV-1 from Africa by full genome sequencing
21. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants
22. HIV's evasion of the cellular immune response
23. The HIV-1 Tat protein: An RNA sequence-specific processivity factor?
24. The HIV-1 Rev protein: Prototype of a novel class of eukaryotic post-transcriptional regulators
25. HLA-class I-specific inhibitory receptors in HIV-1 infection
26. Biological characterization of human immunodeficiency virus type 1 clones derived from different organs of an AIDS patient by long-range PCR
27. Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa
28. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients
29. HIV-1 regulatory/accessory genes: Keys to unraveling viral and host cell biology
30. Human immunodeficiency viruses in the developing world
31. Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef
32. Peptide motifs of HLA-B58, B60, B61, and B62 molecules
33. Presence of diverse human immunodeficiency virus type 1 viral variants in Cameroon
34. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides
35. A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells
36. Tat as one key to HIV-induced immune pathogenesis and Tat (correction of Pat) toxoid as an important component of a vaccine
37. A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1
38. HIV-1 Tat protein as a potential AIDS vaccine
39. Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses
40. Rapid characterization of HIV clade C-specific cytotoxic T lymphocyte responses in infected African children and adults
41. Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by Elispot and intracellular cytokine staining assays
42. Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection
43. Differential narrow focusing of immunodominant human immunodeficiency virus Gag-specific cytotoxic T-lymphocyte responses in infected African and Caucasoid adults and children
44. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS
45. Anti-HIV cellular immunity: Recent advances towards vaccine design
46. Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children
47. The great escape-AIDS viruses and immune control
48. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients
49. BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT
50. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya
51. HIV vaccines: Where we are and where we are going
52. New class I and II HLA alleles strongly associated with opposite patterns of progression to AIDS
53. Predominance of HIV-1 subtype A and D infections in Uganda
54. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
55. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
56. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
57. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression
58. Numbering positions in HIV relative to HXB2CG, p. III-102-III-111
59. HIV molecular immunology database 1999
60. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
61. Definition of peptide binding motifs amongst the HLA-A*30 allelic group
62. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
63. Progress in the development of an HIV-1 vaccine
64. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination
65. Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection
66. Subtype G and multiple forms of A/G intersubtype recombinant human immunodeficiency virus type 1 in Nigeria
67. Escape of human immunodeficiency virus from immune control
68. Molecular evolution of mRNA: A method for estimating evolutionary rates of synonymous and amino acid substitutions from homologous nucleotide sequences and its application
69. An infectious DNA clone of HIV type 1 subtype C
70. Most env and gag subtype A HIV-1 viruses circulating in West and West Central Africa are similar to the prototype AG recombinant virus IBNG
71. Molecular cloning and biological characterization of fulllength HIV-1 subtype C from Botswana
72. Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions
73. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya
74. Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene
75. Distribution of HIV-1 subtypes among HIV-seropositive patients in the interior of Cote d'Ivoire
76. Identification of most frequent HLA class I antigen specificities in Botswana: Relevance for HIV vaccine design
77. HIV type 1 A/J recombinant with a pronounced pol gene mosaicism
78. Molecular cloning and phylogenetic analysis of HIV-1 subtype C: A set of 23 full-length clones from Botswana
79. Four novel CTL epitopes in the highly-conserved MHR region of HIV-1 gag, restricted by B*4402, B*1401, A*2601 and B*70
80. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
81. Mechanisms of molecular evolution
82. Variance and covariances of the numbers of synonymous and nonsynonymous substitutions per site
83. TREEVIEW: An application to display phylogenetic trees on personal computers
84. Cross-protection in NYVAC-HIV-1-immunized/HIV-2-challenged but not in NYVAC-HIV-2-immunized/SHIV-challenged rhesus macaques
85. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques
86. WWW-query: An on-line retrieval system for biological sequence banks
87. + T cell response to HIV-1
88. The HIV-1 Rev protein
89. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
90. HLA-B15 peptide ligands are preferentially anchored at their C termini
91. SWAN: Sliding window analysis of nucleotide sequence variability
92. MHC ligands and peptide motifs
93. HIV-1 nomenclature proposal
94. Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents
95. + T cell responses associated with control of viremia
96. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
97. Full-length sequence of an Ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C
98. Molecular evolution of human immunodeficiency virus type 1 subtype A Senegal: 1988-1997
99. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution
100. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
101. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism
102. - T cells
103. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice
104. Identification of all HIV type 1 group M subtypes in Senegal, a country with low and stable seroprevalence
105. Differences in chemokine coreceptor usage between genetic subtypes of HIV-1
106. HIV-specific cytotoxic T lymphocytes in seropositive individuals
107. CCR5 co-receptor utilization involves a highly conserved arginine residue of human immunodeficiency virus type 1 gp120
108. Analysis of HLA frequencies in population cohorts for design of HLA-based HIV vaccines, p. IV-10-IV-16
109. Cross-clade envelope glycoprotein 160-specific CDS+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection
110. Codonsubstitution models for heterogeneous selection pressure at amino acid sites